Valeant Pharmaceuticals ($VRX) has plenty on its plate, what with its sagging stock price, debt load and a host of investigations. Adding just a little more to the pile is a recent recall of more than half a million bottles of one of its gastrointestinal drugs.
The Canadian-based drugmaker is voluntarily recalling 564,454 bottles, 32 lots, of chlordiazepoxide HCl/clidinium bromide capsules, a generic version of Librax. Then it is recalling another 6,321 bottles of branded Librax. The drug combines in a single-capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide to control emotional and somatic factors in gastrointestinal disorders.
The recalls began in April and were listed this week on the FDA Enforcement Report website. The products were manufactured at Valeant’s plant in Steinbach, Manitoba, Canada. That is the same plant that the drugmaker said last week would get $15 million in investments this year in manufacturing upgrades and to handle the transfer of North American production of GI drugs Xifaxan and Apriso.
The drugmaker also said it will spend $12.5 million on its Laval, Quebec, facility. That investment will cover the transfer of production of Arestin, an antibiotic used in periodontal treatments. The Laval expansion will result in 15 jobs being added at the facility.
Valeant had to deal with another significant recall earlier in the year when its Bausch + Lomb unit voluntarily initiated a massive recall of an eye dilation med after learning at least some bottles had been shipped with the wrong medication insert. It recalled more than 1,090,000 bottles of Tropicamide Ophthalmic Solution USP, 1%.
- access the reports here
Related Articles:
Debt-ridden Valeant invests $27.5M in manufacturing
Valeant's Bausch + Lomb recalls more than 1M bottles of eye med